Clark Estates Inc’s Catalyst Pharmaceutical CPRX Stock Holding History

Clark Estates Inc’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.58M	Hold	113,918	–	–	0.83%	20
2026 Q1	$2.82M	Hold	113,918	–	–	0.68%	22
2025 Q4	$2.66M	Hold	113,918	–	–	0.65%	26
2025 Q3	$2.24M	Hold	113,918	–	–	0.51%	46
2025 Q2	$2.47M	Sell	113,918 -20,500	-15%	-$484K	0.55%	22
2025 Q1	$3.26M	Sell	134,418 -51,325	-28%	-$1.16M	0.69%	17
2024 Q4	$3.88M	Sell	185,743 -22,507	-11%	-$484K	0.75%	20
2024 Q3	$4.14M	Sell	208,250 -16,700	-7%	-$310K	0.77%	21
2024 Q2	$3.48M	Sell	224,950 -6,050	-3%	-$94.2K	0.65%	35
2024 Q1	$3.68M	Buy	231,000 +33,500	+17%	+$505K	0.61%	41
2023 Q4	$3.32M	Buy	197,500 +9,500	+5%	+$130K	0.56%	56
2023 Q3	$2.2M	Buy	+188,000	New	+$2.51M	0.4%	79

Other funds holding CPRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clark Estates Inc's CPRX Position: Q2 2026 in Review

Clark Estates Inc held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 113,918 shares worth $3.58M. The position accounts for 0.83% of the portfolio, ranked #20.

Clark Estates Inc first reported a position in CPRX in Q3 2023 and has held it in 12 quarters since. The position peaked at $4.14M in Q3 2024. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

Clark Estates Inc held 113,918 shares of Catalyst Pharmaceutical worth $3.58M as of Q2 2026.
Clark Estates Inc left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
Catalyst Pharmaceutical made up 0.83% of Clark Estates Inc's portfolio in Q2 2026, its #20 holding.
Clark Estates Inc first reported a position in Catalyst Pharmaceutical in Q3 2023 and has held it in 12 quarters since.
Clark Estates Inc's Catalyst Pharmaceutical position peaked at $4.14M in Q3 2024.
395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Clark Estates Inc's 13F filing for Q2 2026, filed 5 Aug 2026.